SCRS Resource Guide Network

Sites, Sponsors, CROs: Discover the solutions your clinical research teams need with SCRS.


We are uniting science, technology and talent to get ahead of disease together.


GSK is a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics, genomics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology,

GSK press releasesGSK press releases 
  • Statement: Zantac (ranitidine) litigation – Kasza case June 10, 2024 2:03pm

    GSK welcomes the plaintiff's voluntary dismissal of Zantac case (Kasza) in Illinois.
    View this post

  • Statement: Zantac (ranitidine) litigation – GSK starts process for appeal of recent Delaware Daubert decision June 10, 2024 12:34pm

    GSK confirms that the Company has taken the first step to seek appeal of the recent Daubert ruling, made by the Delaware Superior Court.
    View this post

  • US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk June 7, 2024 9:01am

    Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes.
    View this post

  • GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies June 6, 2024 7:54am

    Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
    View this post

  • Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer June 3, 2024 9:00am

    Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024.
    View this post

  • Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma June 2, 2024 11:46am

    DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement.
    View this post

Web Site: www.gsk.com 


  • GlaxoSmithKline
    Pharmaceutical Manufacturing
    980 Great West Road
    United States
    Map It »
  • Videos4
  • News6
  • Last UpdatedJuly 24, 2023 12:39pm EDT